Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "central"

837 News Found

Mylab’s CoviSelf can detect Omicron: Study
Medical Device | January 10, 2022

Mylab’s CoviSelf can detect Omicron: Study

Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully


Lilly and Entos  collaborate for therapies in multiple neurologic indications
Biotech | January 07, 2022

Lilly and Entos collaborate for therapies in multiple neurologic indications

Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly


Tata Medical develops OmiSure to detect Omicron
Medical Device | January 05, 2022

Tata Medical develops OmiSure to detect Omicron

The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes


Study demonstrates Covaxin safe for kids in the age 2-18 years
News | December 30, 2021

Study demonstrates Covaxin safe for kids in the age 2-18 years

Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults


JB Chemicals and Pharmaceuticals to launch molnupiravir next month
Drug Approval | December 29, 2021

JB Chemicals and Pharmaceuticals to launch molnupiravir next month

It will be marketed under the brand name Molunamax


Cipla receives EUA for Cipmolnu
Drug Approval | December 28, 2021

Cipla receives EUA for Cipmolnu

The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use


CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax
News | December 28, 2021

CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax

All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.


Expectations and predictions for 2022
Opinion | December 28, 2021

Expectations and predictions for 2022

In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc


Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis
Biotech | December 24, 2021

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis

Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000


Stelis commissions vaccine facility in Bengaluru
News | December 21, 2021

Stelis commissions vaccine facility in Bengaluru

The company has started manufacturing the Sputnik Light vaccine